Gene Expression Profiling in Malignant Pleural Mesothelioma: Implications for PARP Inhibitor and Chemotherapy Response

Study Background and Research Question

Malignant pleural mesothelioma (MPM) is an aggressive neoplasm arising from the pleura, characterized by limited therapeutic options and a median survival of approximately 12 months, even with systemic combination therapies. The current standard of care for unresectable or advanced MPM involves chemotherapy with cisplatin and pemetrexed, but response rates remain unsatisfactory, typically around 40%, with most patients experiencing disease progression or recurrence. The underlying causes of this intrinsic or acquired resistance to chemotherapy are poorly understood, impeding the development of more effective strategies. Borchert et al. (2019) addressed whether defects in homologous recombination repair (HRR)—collectively referred to as 'BRCAness'—could serve as biomarkers for vulnerability to targeted therapies, particularly PARP inhibitors, in MPM.

Key Innovation from the Reference Study

The central innovation of the study lies in the systematic profiling of HRR pathway gene expression in both MPM cell lines and clinical tumor samples, with the aim of identifying a BRCAness phenotype beyond classical BRCA1/2 mutations. The authors hypothesized that such defects would render MPM cells reliant on alternative DNA repair mechanisms, such as PARP1-mediated repair, and therefore susceptible to synthetic lethality upon PARP inhibition. Importantly, the study links specific gene expression signatures—including BAP1 mutations—to functional vulnerabilities that could be therapeutically exploited using olaparib, a PARP inhibitor.

Methods and Experimental Design Insights

Borchert et al. evaluated three established MPM cell lines (including BAP1-mutated NCI-H2452) and primary lung fibroblasts as controls. The experimental approach integrated:

• Treatment of cell lines with pemetrexed, cisplatin, olaparib, and combination regimens to assess cytotoxicity, apoptosis, and senescence.
• Digital gene expression profiling of 91 clinical MPM tumor samples, focusing on a curated panel of HRR pathway genes associated with BRCAness.
• Correlation analyses between gene expression signatures and therapeutic response, using both in vitro models and clinical data.

Functional readouts included cell viability assays, apoptosis markers, and senescence-associated β-galactosidase staining. Gene expression analysis enabled the identification of prognostic markers and the stratification of patient tumors by HRR competency.

Core Findings and Why They Matter

The study demonstrated several meaningful findings with direct implications for cancer chemotherapy research:

• BRCAness Phenotype in MPM: Approximately 10% of clinical MPM samples exhibited gene expression signatures consistent with BRCAness, including loss-of-function mutations in BAP1—a gene mutated in 26–64% of MPM cases according to the reference study.
• PARP Inhibitor Sensitivity: BAP1-mutant MPM cell lines displayed pronounced sensitivity to olaparib, especially when combined with cisplatin. This combination induced higher levels of apoptosis and senescence than either agent alone, indicating a synergistic effect in HR-compromised cells.
• Prognostic Gene Markers: The expression levels of AURKA, RAD50, and DDB2 were identified as potential prognostic indicators, allowing further stratification of patients and prediction of therapeutic response.
• Therapeutic Stratification: The functional link between HRR defects and PARP inhibitor sensitivity opens new avenues for personalized treatment of MPM. The data indicate that up to two-thirds of patients could benefit from combination strategies that exploit synthetic lethality in HR-deficient tumors.

These findings underscore the need for robust biomarker-driven approaches in the development of next-generation chemotherapy regimens and support the integration of molecular diagnostics into clinical decision-making for MPM.

Comparison with Existing Internal Articles

The insights from Borchert et al. align with and extend the mechanistic frameworks discussed in several recent reviews and translational oncology resources. For example, the article "Gene Signatures in Mesothelioma Predict Olaparib and Pemetrexed Response" contextualizes the reference study's gene expression findings within the broader challenge of precision chemotherapy, highlighting the potential for pemetrexed to be used strategically in combination with DNA repair pathway inhibitors. Similarly, "Pemetrexed in Translational Oncology: Mechanisms and Strategy" synthesizes experimental evidence for pemetrexed’s multi-target antifolate activity, emphasizing its role in overcoming resistance in tumor cell models with defined DNA repair vulnerabilities.

These internal resources collectively reinforce the strategy of integrating HRR profiling into preclinical and clinical research workflows. They also highlight the importance of combining established antiproliferative agents, such as pemetrexed disodium, with novel targeted therapies to maximize therapeutic efficacy against resistant malignancies such as MPM.

Limitations and Transferability

While the study provides compelling preclinical evidence, several limitations should be noted:

• The in vitro models, though informative, may not fully recapitulate the complexity of the tumor microenvironment and immune interactions in vivo.
• The proportion of MPM patients with actionable BRCAness signatures is variable and may differ across cohorts due to genetic heterogeneity.
• Clinical translation of combination regimens involving PARP inhibitors and platinum-based agents requires careful optimization to manage toxicity and resistance.
• The predictive value of specific gene markers (e.g., AURKA, RAD50, DDB2) warrants further validation in prospective clinical studies.

Nevertheless, the gene expression profiling approach outlined by Borchert et al. is highly transferable to other cancer types where HRR deficiency may drive therapeutic sensitivity, supporting broader application in precision oncology research.

Protocol Parameters

• Cell line selection: Use well-characterized MPM cell lines (e.g., NCI-H2452 for BAP1 mutant models) and matched controls for differential drug response studies.
• Drug treatment: Pemetrexed is typically applied at 0.0001–30 μM for 72-hour exposures in vitro to assess antiproliferative effects, as reported in the product information. For combination protocols, olaparib and cisplatin can be added either sequentially or simultaneously to probe synergy.
• Gene expression profiling: Employ digital or qPCR-based platforms to quantify HRR pathway gene panels (including BAP1, AURKA, RAD50, DDB2) in tumor samples or cell lines.
• Apoptosis and senescence assays: Assess apoptosis using Annexin V/PI staining and senescence via β-galactosidase activity after drug treatment.
• Clinical sample analysis: When feasible, annotate gene expression data with clinical outcomes to refine predictive biomarker models.

Research Support Resources

To facilitate research on DNA damage response, chemotherapy resistance, and combination regimens in MPM and related tumor models, investigators can utilize Pemetrexed (SKU A4390) as a reference multi-target antifolate antimetabolite, following literature-backed dosing and storage guidelines. This reagent supports in vitro and in vivo studies of nucleotide biosynthesis inhibition and can be used in combination with PARP inhibitors to model synthetic lethality in HR-compromised cell systems. For mechanistic rationale and advanced experimental strategies, researchers may consult recent translational reviews integrating gene expression profiling with antifolate-based chemotherapy research. APExBIO provides detailed compound specifications to ensure reproducibility in cancer cell line and xenograft studies.